Welcome to the Starpharma investor centre.

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Need to update your
shareholder details

 

Download 
Annual Report

View the 
Analyst coverage

 

Have an
Investor query?

 

Register here
for email updates

Latest News & Announcements

Click here for news archive

9 August 2017

Starpharma and Monash awarded STEM+ Business Fellowships

Starpharma today announced that Starpharma and Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. 

Read more

7 August 2017

Successful VivaGel® Phase 3 results and NDA planned for rBV

Starpharma today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data.

Read more

19 July 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2017.

Read more

4 July 2017

Shareholder Update July 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 ( pdf file, 710kb)

4 July 2017

VivaGel® BV phase 3 results timing and commercialisation

Starpharma today announced revised timing for results of its two pivotal VivaGel® BV phase 3 trials for the prevention of recurrent bacterial vaginosis – now expected to be available in late July/early August 2017. 

Read more

14 June 2017

Sale of Agrochemicals Business Investor Presentation

Melbourne, Australia; 14 June 2017: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), will be holding an investor conference call today at 11am (AEST) to discuss the sale of its Agrochemicals business to Agrium Inc., for $35 million. A presentation featuring further information on the transaction is available.

Read more

14 June 2017

Starpharma sells Agrochemicals business to Agrium for $35M

Melbourne, Australia; 14 June 2017: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business willl be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc.

Read more

6 June 2017

DEP® irinotecan outperforms irinotecan in multiple cancer models

Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its proprietary DEP® irinotecan has demonstrated significantly better anti‑tumour activity and increased survival compared with irinotecan in a variety of human colon cancer models. 

Read more

2 June 2017

Starpharma receives DEP® milestone from AstraZeneca

Starpharma today announced it has received A$2.6 million from AstraZeneca following the achievement of the final preclinical milestone for its first DEP® candidate, a highly novel oncology molecule from AstraZeneca’s portfolio. 

Read more

28 April 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2017.

Read more

20 April 2017

AstraZeneca DEP® candidate advance triggers milestone to Starpharma

 Starpharma announced the achievement of a key preclinical milestone for its DEP® drug delivery technology in combination with a proprietary oncology molecule from AstraZeneca.

Read more

12 April 2017

Ansell launches VivaGel® condom in Canada

Starpharma is pleased to announce the VivaGel® condom has been launched in Canada by Ansell under the LifeStyles® Dual Protect brand. 

Read more
12 3 ... Next

Reports & Presentations

Click here for financial reports archive

27 February 2017

Interim Report and Half-Yearly Financial Results

Starpharma released its interim report and financial results for the half-year ended 31 December 2016.

 

Financial Summary

  • Reported loss of $9.0M (Dec 2015: $10.0M)
  • R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
  • Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
  • Receipt of $3.5M R&D tax incentive refund from FY16
Read more

31 January 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

Read more

8 November 2016

Starpharma to present at Bio-Europe conference

Starpharma will be presenting at the Bio-Europe® conference held in Cologne, Germany this week. At the conference Starpharma will also be conducting licensing discussions for DEP™ and VivaGel® with pharmaceutical companies.

Read more

26 October 2016

Starpharma to present at US Drug Delivery Conference

Starpharma will be presenting its DEP™ platform at the 6th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 27-28 October.

Read more

25 October 2016

Starpharma to present at ASX Spotlight in Asia

Starpharma presents to more than 300 sophisticated and institutional investors as part of the ASX Spotlight Conference in Hong Kong and Singapore.

Read more

30 August 2016

Highlights of FY2016 Presentation: FNN Interview

Starpharma advises a brief audio interview and presentation with Chief Executive Officer Dr Jackie Fairley will be broadcast today by the Finance News Network.

Read more

29 August 2016

Annual Report and full year financial results

Starpharma released its annual report and financial results for the year ended 30 June 2016.

 Financial Results

  • Net cash burn (cash outflows before new capital) $17.5M
  • Cash position at end of the year $46.0M
  • Net proceeds of $32.6M from equity placement and share purchase plan
  • Total revenue and other income $4.6M including the first US$2M DEP™ milestone from AstraZeneca
  • Reported loss $22.7M
  • Receipt of $3.4M R&D tax incentive
Read more

In the Media

Click here for more In the Media

23 June 2017

Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base

The sale of Starpharma’s agrochemical business was recently covered in Farm Weekly, highlighting the unique opportunity that Starpharma’s Priostar® dendrimer technology brings to the agrochemical market and the commercial value Agrium saw in the technology. In the article, Starpharma CEO Dr Jackie Fairley details the sale, including the patent transfer, total sale proceeds and the implications for the Company.

Go to article (external link)

20 June 2017

Starpharma featured on Business IQ, Sky Business News

Starpharma CEO Dr Jackie Fairley was interviewed on Sky Business News where she spoke to Business IQ host James Daggar-Nickson about dendrimer technologies and how the company develops products for a wide range of applications using the platform technology. Dr Fairley also discussed Australian innovation and the company's recent sale of its agrochemical business to global agricultural product giant Agrium.

Go to clip (external link)

14 June 2017

Finance News Network: Starpharma sells Agrochemicals business for $35M

Finance News Network noted Starpharma’s transaction to sell Starpharma Agrochemicals to Agrium Inc. for A$35M in cash consideration. The piece added that cash proceeds from the sale will allow Starpharma to focus on its core pharmaceutical development portfolio.

Go to the article (external link) 

14 June 2017

Starpharma’s sale of its agrochemical business to Agrium for A$35M noted in The Land

The sale of Starpharma’s agrochemical business was covered in The Land, with the article highlighting the innovation behind the Priostar® technology and how Agrium saw the acquisition as a strategic fit for their product portfolio. 

Go to article (external link)

20 April 2017

Starpharma featured on Ticky on Sky Business News

Starpharma CEO Dr Jackie Fairley was interviewed on Ticky on Sky Business News where she discussed the company's VivaGel® portfolio, its DEP® drug delivery technology and its relationship with global pharmaceutical giant AstraZeneca.

 Go to the article (external link)

12 April 2017

Melbourne-based company develops world's first anti-viral condom

 

The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.

 Go to the article (external link)

30 March 2017

VivaGel BV phase 3 trials for prevention of BV completed

Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.

 Go to the article (external link)

13 January 2017

Starpharma VivaGel® BV gets FDA fast track

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

1 August 2016

The Australian: Starpharma perks up on China condom deal

The Australian’s David Rogers reports that Starpharma has signed “an exclusive license and supply agreement with Shenyang SKY and Land Latex Co for the manufacture and sale of VivaGel condoms to the Government segment of the Chinese condom market”.

Go to the article (external link)

17 May 2016

The Conversation: Antiviral condoms will help protect Australian Olympians from STIs – here’s how

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

© Starpharma Holdings Limited 2017